Aricept Complexed with Acetylcholinesterase
From Proteopedia
(Difference between revisions)
| (5 intermediate revisions not shown.) | |||
| Line 2: | Line 2: | ||
[[Image:E2020_interactins_in_AChE_gorge.jpg|left|250px]]<br /> | [[Image:E2020_interactins_in_AChE_gorge.jpg|left|250px]]<br /> | ||
'''3D structure of anti-Alzheimer's drug, Aricept, complexed with acetylcholinesterase''' | '''3D structure of anti-Alzheimer's drug, Aricept, complexed with acetylcholinesterase''' | ||
| - | (see also [[AChE | + | (see also [[AChE inhibitors and substrates]]) |
==Background== | ==Background== | ||
Several cholinesterase inhibitors are either being utilized for symptomatic treatment of Alzheimer's disease or are in advanced clinical trials. '''E2020''', marketed as '''Aricept''', is a member of a large family of N-benzylpiperidine-based [[acetylcholinesterase]] (AChE) inhibitors, developed, synthesized and evaluated by the Eisai Company in Japan. These inhibitors were designed on the basis of QSAR studies prior to elucidation of the 3D structure of ''Torpedo californica'' AChE (''Tc''AChE) ([[1ea5]]). It significantly enhances performance in animal models of cholinergic hypofunction and has a high affinity for AChE, binding to both electric eel and mouse AChE in the nanomolar range. | Several cholinesterase inhibitors are either being utilized for symptomatic treatment of Alzheimer's disease or are in advanced clinical trials. '''E2020''', marketed as '''Aricept''', is a member of a large family of N-benzylpiperidine-based [[acetylcholinesterase]] (AChE) inhibitors, developed, synthesized and evaluated by the Eisai Company in Japan. These inhibitors were designed on the basis of QSAR studies prior to elucidation of the 3D structure of ''Torpedo californica'' AChE (''Tc''AChE) ([[1ea5]]). It significantly enhances performance in animal models of cholinergic hypofunction and has a high affinity for AChE, binding to both electric eel and mouse AChE in the nanomolar range. | ||
| Line 14: | Line 14: | ||
The X-ray structure shows, a posteriori, that the design of E2020 took advantage of several important features of the active-site gorge of AChE, to produce a drug with both high affinity for AChE and a high degree of selectivity for AChE versus butyrylcholinesterase (BChE). It also delineates voids within the gorge that are not occupied by E2020 and could provide sites for potential modification of E2020 to produce drugs with improved pharmacological profiles. | The X-ray structure shows, a posteriori, that the design of E2020 took advantage of several important features of the active-site gorge of AChE, to produce a drug with both high affinity for AChE and a high degree of selectivity for AChE versus butyrylcholinesterase (BChE). It also delineates voids within the gorge that are not occupied by E2020 and could provide sites for potential modification of E2020 to produce drugs with improved pharmacological profiles. | ||
| - | == | + | ==About this Structure== |
| - | 1EVE | + | 1EVE is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Torpedo_californica Torpedo californica]. The June 2004 RCSB PDB [http://pdb.rcsb.org/pdb/static.do?p=education_discussion/molecule_of_the_month/index.html Molecule of the Month] feature on ''Acetylcholinesterase'' by David S. Goodsell is [http://dx.doi.org/10.2210/rcsb_pdb/mom_2004_6 10.2210/rcsb_pdb/mom_2004_6]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1EVE OCA]. |
| + | |||
| + | ==Additional Resources== | ||
| + | For additional information, see: [[Alzheimer's Disease]]<br /> | ||
| - | ==Nguồn bổ sung== | ||
| - | Thông tin chi tiết, liên hệ: [[Alzheimer's Disease]] | ||
<br /> | <br /> | ||
</StructureSection> | </StructureSection> | ||
| - | == | + | ==Reference== |
| - | Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=10368299 10368299] | + | Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:[http://ispc.weizmann.ac.il//pmbin/getpm?pmid=10368299 10368299] |
| - | [[ar: | + | [[ar:Aricept_Complexed_with_Acetylcholinesterase (Arabic)]] |
| - | [[ca: | + | [[ca:Aricept_Complexed_with_Acetylcholinesterase (Catalan)]] |
| - | [[cs: | + | [[zh:Aricept_Complexed_with_Acetylcholinesterase (Chinese)]] |
| - | [[de: | + | [[cs:Aricept_Complexed_with_Acetylcholinesterase (Czech)]] |
| - | [[en: | + | [[de:Aricept_Complexed_with_Acetylcholinesterase (German)]] |
| - | [[es: | + | [[en:Aricept_Complexed_with_Acetylcholinesterase]] |
| - | [[fr: | + | [[es:Aricept_Complexed_with_Acetylcholinesterase (Spanish)]] |
| - | [[he: | + | [[fr:Aricept_Complexed_with_Acetylcholinesterase (French)]] |
| - | [[it: | + | [[he:Aricept_Complexed_with_Acetylcholinesterase (Hebrew)]] |
| - | [[ru: | + | [[it:Aricept_Complexed_with_Acetylcholinesterase (Italian)]] |
| - | [[sk: | + | [[ru:Aricept_Complexed_with_Acetylcholinesterase (Russian)]] |
| - | [[ | + | [[sk:Aricept_Complexed_with_Acetylcholinesterase (Slovak)]] |
| - | [[ | + | [[vi:Aricept_Complexed_with_Acetylcholinesterase (Vietnamese)]] |
| - | [[ | + | [[tr:Aricept_Complexed_with_Acetylcholinesterase (Turkish)]] |
| + | [[hi:Aricept Complexed with_Acetylcholinesterase (Hindi)]]<br /> | ||
[[Category: Acetylcholinesterase]] | [[Category: Acetylcholinesterase]] | ||
Current revision
| |||||||||||
Reference
Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs., Kryger G, Silman I, Sussman JL, Structure. 1999 Mar 15;7(3):297-307. PMID:10368299
Proteopedia Page Contributors and Editors (what is this?)
Eran Hodis, Joel L. Sussman, Jaime Prilusky, Alexander Berchansky, OCA, Michal Harel, David Canner, Wayne Decatur, Pham Ngoc Phuong, Angel Herraez, Lucie Kolarova
